Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 57Immunoglobulin Light-chain Amyloidosis 5Smoldering Multiple Myeloma 4Plasmacytoma 3Leukemia, Plasma Cell 3Renal Insufficiency 1Recurrence 1POEMS Syndrome 1Chromosome 17 deletion 1Anemia 1Amyloidosis 1

Interventions

Dexamethasone 21Calcium Dobesilate 10Melphalan 9Bortezomib 8Cyclophosphamide 7Lenalidomide 6pomalidomide 4venetoclax 3miridesap 3daratumumab 3ixazomib 2belantamab mafodotin 2Thalidomide 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1isatuximab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Amyloidosis × auricularum × Plasma cell × Clear all
NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡